Table 9.6a

Immunosuppression Use for Induction, 1997 to 2006

Recipients with Liver Transplants

  Year of Transplant
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Transplants 4,188 4,516 4,751 4,995 5,191 5,331 5,673 6,169 6,441 6,649
With Immunosuppression Info 3,870 4,199 4,441 4,845 5,029 5,197 5,520 5,972 6,161 6,380
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 2.1% 1.2% 0.7% 0.7% 0.4% 0.5% 0.5% 0.4% 0.2% 0.3%
OKT3 4.9% 3.6% 1.4% 0.8% 0.7% 0.3% 0.3% 0.2% 0.8% 2.7%
Thymoglobulin 0.0% 0.1% 0.5% 1.2% 2.4% 4.2% 6.5% 7.4% 7.2% 8.9%
Zenapax 0.0% 2.9% 6.6% 6.6% 5.8% 4.6% 5.6% 4.7% 4.0% 5.7%
Simulect 0.1% 1.4% 4.4% 6.6% 6.2% 7.8% 7.2% 6.4% 7.1% 6.5%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.7% 1.6% 1.6% 1.4%
No Induction Drugs Recorded 92.9% 91.0% 86.7% 84.5% 84.6% 82.7% 79.5% 79.5% 79.9% 77.3%


Source: OPTN/SRTR Data as of May 1, 2007.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.